Brent Saun­ders was think­ing a lot about skin­care and longevi­ty dur­ing the Covid-19 pan­dem­ic, short­ly af­ter he fin­ished up the more than $60 bil­lion sale of Al­ler­gan to Ab­b­Vie. Af­ter ...

The phar­ma in­dus­try is yet again tak­ing the gov­ern­ment to court over its lat­est ef­fort to con­trol US drug prices. Last week, the Trump ad­min­is­tra­tion fi­nal­ized a demon­stra­tion ...

Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient ...

Welcome back to Endpoints Weekly! We unveiled our 2026 Women in Biopharma special project on Monday. Our team pored through nearly 200 nominations to reach this year’s list of 20 ...

IPOs on Nasdaq, backed by Eli Lilly, focusing on Treg science for autoimmune disorders. Pipeline includes TRB-061 and a CD30 agonist for IBD.

PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...

City Therapeutics eyes $158M IPO; Iambic Therapeutics targets $135M; Alchemist Capital launches with $100M; Life Biosciences ...

WHO releases preeclampsia roadmap; Comanche, DiaMedica, Avilar & ProFound developing treatments; Eli Lilly exploring the ...

Chan Zuckerberg Biohub launches $1.8B Virtual Biology Initiative with Meta, Google DeepMind, Isomorphic Labs, DOE, and NIH to ...

Ultragenyx sells a rare pediatric disease PRV for $210M, one of 2026's priciest voucher deals, and plans to monetize a second ...

Biohaven licenses pan-IgG degraders to Ono for $80M; UK pulls Ixchiq; ADC raises $86.6M; BMS Zenbexus Phase 3 win; Pfizer ...

Leerink's David Risinger downgrades Bristol Myers to market perform and cuts his price target to $59, citing doubts on ...